Cargando…

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Detalles Bibliográficos
Autores principales:	Romiti, R., Valenzuela, F., Chouela, E.N., Xu, W., Pangallo, B., Moriarty, S.R., Gürbüz, S., Riedl, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900236/ https://www.ncbi.nlm.nih.gov/pubmed/30609008 http://dx.doi.org/10.1111/bjd.17604

Ejemplares similares

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis
por: Huang, He, et al.
Publicado: (2023)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
por: Kazemi, Tiana, et al.
Publicado: (2017)

Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report
por: Herrera-Acosta, Enrique, et al.
Publicado: (2021)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
por: Smith, Saxon D., et al.
Publicado: (2023)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
por: María, Pablo Santa, et al.
Publicado: (2017)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
por: PAPP, Kim, et al.
Publicado: (2022)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
por: Giunta, Alessandro, et al.
Publicado: (2017)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis
por: Merola, J.F., et al.
Publicado: (2020)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis
por: Mu, Xin, et al.
Publicado: (2021)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)
por: Callis Duffin, K., et al.
Publicado: (2016)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
por: Ying, Li, et al.
Publicado: (2023)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
por: Yosipovitch, Gil, et al.
Publicado: (2018)

Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient
por: Vinaixa Aranzazu, Arrieta, et al.
Publicado: (2021)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
por: Ghoneim, Sara, et al.
Publicado: (2017)

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis
por: Xia, Rui Yuan, et al.
Publicado: (2023)

What are the barriers to physical activity in patients with chronic plaque psoriasis?
por: Auker, L., et al.
Publicado: (2020)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient
por: Megna, Matteo, et al.
Publicado: (2022)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report
por: Smith, Matthew K., et al.
Publicado: (2019)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gvh1k4ep0j9lg4u24hv586007r